Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xerxes Pundole

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Arthritis Care & Research|September 24, 2021
Systemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast CancerSebastian Bruera, Xiudong Lei, Xerxes Pundole, et al.
The Oncologist|August 21, 2025
Efficacy Outcomes Between Tarlatamab and Real-World Physicians' Choice of Therapies for Previously Treated Extensive Stage Small Cell Lung CancerJessie Wang, Gautam Sajeev, Xinglei Chai, et al.
Advances in Therapy|October 8, 2025
Matching-Adjusted Indirect Treatment Comparison of Tarlatamab Versus Comparator Therapies in England in Patients with Extensive-Stage Small Cell Lung Cancer Who Have Received Two or More Prior Lines of TherapyRumbidzai Takundwa, Gaurav Suri, Franziska Dirnberger, et al.
Clinical Rheumatology|August 18, 2020
Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapyXerxes Pundole, Natalia V Zamora, Harish Siddhanamatha, et al.
Clinical Rheumatology|December 20, 2019
Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancerXerxes Pundole, Natalia V Zamora, Harish Siddhanamatha, et al.
JAMA Network Open|April 1, 2022
Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate CancerMaria E Suarez-Almazor, Xerxes Pundole, Gerardo Cabanillas, et al.
Immunotherapy|September 9, 2020
Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case reportXerxes Pundole, Amy Little Jones, Michael T Tetzlaff, et al.
Bonekey Reports|December 27, 2016
Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trialHuifang Lu, Richard E Champlin, Uday Popat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 1, 2020
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint InhibitorsJeffrey Aldrich, Xerxes Pundole, Sudhakar Tummala, et al.
The Oncologist|September 30, 2024
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancerJaime Shaw, Xerxes Pundole, Akhila Balasubramanian, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Arthritis Care & Research|September 24, 2021
Systemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast CancerSebastian Bruera, Xiudong Lei, Xerxes Pundole, et al.
The Oncologist|August 21, 2025
Efficacy Outcomes Between Tarlatamab and Real-World Physicians' Choice of Therapies for Previously Treated Extensive Stage Small Cell Lung CancerJessie Wang, Gautam Sajeev, Xinglei Chai, et al.
Advances in Therapy|October 8, 2025
Matching-Adjusted Indirect Treatment Comparison of Tarlatamab Versus Comparator Therapies in England in Patients with Extensive-Stage Small Cell Lung Cancer Who Have Received Two or More Prior Lines of TherapyRumbidzai Takundwa, Gaurav Suri, Franziska Dirnberger, et al.
Clinical Rheumatology|August 18, 2020
Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapyXerxes Pundole, Natalia V Zamora, Harish Siddhanamatha, et al.
Clinical Rheumatology|December 20, 2019
Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancerXerxes Pundole, Natalia V Zamora, Harish Siddhanamatha, et al.
JAMA Network Open|April 1, 2022
Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate CancerMaria E Suarez-Almazor, Xerxes Pundole, Gerardo Cabanillas, et al.
Immunotherapy|September 9, 2020
Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case reportXerxes Pundole, Amy Little Jones, Michael T Tetzlaff, et al.
Bonekey Reports|December 27, 2016
Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trialHuifang Lu, Richard E Champlin, Uday Popat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 1, 2020
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint InhibitorsJeffrey Aldrich, Xerxes Pundole, Sudhakar Tummala, et al.
The Oncologist|September 30, 2024
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancerJaime Shaw, Xerxes Pundole, Akhila Balasubramanian, et al.
Pageof 4